Dale Halter
Rheumatology · Houston, TXNPI 1083617310
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Novartis at 40.0% of the total.
Across 177 payments — averaging $148.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- United Rheumatology$10K
- Amgen$3K
- AbbVie$351
- E.r. Squibb & Sons, L.L.C.$340
- Pfizer$321
- plus $1K from 11 others
Across 2 payments — averaging $4135.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
What the payments were for
- Consulting fees$10,04038%
- Speaking & faculty fees$11,25143%
- Travel & lodging$1,3395%
- Food & beverage$3,48213%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $10,495 |
| United Rheumatology | 1 | $10,000 |
| Amgen(2 entities) | 33 | $3,464 |
| AbbVie | 9 | $351 |
| E.r. Squibb & Sons, L.L.C. | 16 | $340 |
| Pfizer | 29 | $321 |
| Sanofi | 12 | $298 |
| UCB, Inc. | 12 | $237 |
| Lilly USA, LLC | 11 | $132 |
| GSK | 8 | $114 |
| Sanofi-aventis U.S. LLC | 2 | $103 |
| Bristol Myers Squibb | 4 | $84 |
| Genentech USA, Inc. | 4 | $75 |
| Radius Health, Inc. | 4 | $72 |
| Medexus Pharma, Inc. | 4 | $58 |
| Johnson & Johnson | 2 | $45 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,210 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Houston
- Naureen AlimHouston$397K
- Shervin AssassiHouston$329K
- Tareq Abou-KhamisHouston$116K
- Maureen MayesHouston$84K
- Maria Suarez AlmazorHouston$72K
- John ReveilleHouston$61K
- Michelle EisenbergHouston$53K
- Alfredo SardinasHouston$52K
- Adnan PeerHouston$49K
- Mujahed AlikhanHouston$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.